Chordate Medical

Chordate Medical is a Swedish medical technology company that has developed Ozilia®, a treatment method based on Kinetic Oscillation Stimulation (KOS), a form of neurostimulation. The company positions Ozilia® as a drug-free alternative to medication for chronic migraine and chronic rhinitis, aiming to relieve pain with few or no unexpected side effects. Chordate Medical has spent more than ten years developing the Ozilia® treatment and holds patents on it in the EU, the United States and many other countries. The Ozilia® treatment for chronic rhinitis has been CE-marked for a long time and is under introduction in selected European markets and Saudi Arabia. The migraine indication received CE marking in May 2021, more than a year earlier than initially planned, and is now being marketed and introduced in Germany, the UK, Italy, Israel and Finland. In August 2021 the Ozilia® Migraine treatment began to be used in regular clinical practice in Sweden. A clinical study was finalized in July 2022 with indications described as very positive. Chordate Medical is listed on the Nasdaq First North Growth Market in Stockholm under the ticker CMH. The company frames its strategy around building an extensive patent portfolio, carrying out clinical trials and demonstrating commercial traction, with a stated goal of building value for an exit. It operates in the neurostimulation/neuromodulation sector, a field it expects to be worth around SEK 132.8 billion globally in 2024, and targets the global migraine drug market, which it expects to be worth around SEK 83.7 billion a year within the next five years. The company is registered as Chordate Medical Holding AB (publ), company number 556962-6319, with its premises at Kista Science Tower, Färögatan 33, Kista, Sweden. It is a Swedish medical technology company listed on Nasdaq First North Growth Market.

Chordate Medical is a Swedish medical technology company that has spent more than ten years developing the Ozilia® treatment, which is based on Kinetic Oscillation Stimulation (KOS), a technique for treating chronic migraine and chronic rhinitis. The company is registered as Chordate Medical Holding AB (publ), company number 556962-6319, and is listed on the Nasdaq First North Growth Market in Stockholm under the ticker CMH. Ozilia® was initially developed and CE-marked exclusively as a treatment for rhinitis. Over time, doctors observed that many patients also experienced improvement in their migraine symptoms, which led the company to investigate how Ozilia® could be used against chronic migraine. The rhinitis treatment has been CE-marked for a long time and is available in the Nordics, on selected markets in the EU, in Israel and in Saudi Arabia. The migraine indication reached a major milestone in May 2021, when Ozilia® received CE marking for the preventive treatment of chronic migraine in adults over 18 years of age, more than a year earlier than the initial plan. In August 2021, the Ozilia® Migraine treatment began to be used for the treatment of chronic migraine in regular clinical practice in Sweden. Marketing and introduction of the migraine indication is now taking place in Germany, the UK, Italy, Israel and Finland, and the treatment is sold in selected European markets as well as in Israel. A clinical study was finalized in July 2022, with indications described as very positive. Chordate Medical has built a patent portfolio covering Ozilia® in the EU and the United States, as well as in many other countries. The company describes its strategy as building value for an exit by expanding its patent portfolio, carrying out clinical trials and demonstrating commercial traction. Chordate Medical operates in the neurostimulation/neuromodulation sector, which it expects to be worth around SEK 132.8 billion globally in 2024. It targets the global migraine drug market, which it expects to be worth around SEK 83.7 billion a year within the next five years. The company's premises are at Kista Science Tower, Färögatan 33, Kista, Sweden. Its annual general meeting in 2025 was held on 21 May 2025, and an extra general meeting was scheduled for 24 April 2026.

• Ozilia® Migraine receives CE marking for preventive treatment of chronic migraine in adults over 18, more than a year earlier than planned.

• Ozilia® Migraine treatment begins to be used in regular clinical practice in Sweden.

• A clinical study is finalized with indications described as very positive.

• Annual General Meeting 2025 held at the company's premises in Kista, Sweden.

• Extra General Meeting scheduled.

Drug-free neurostimulation alternative to medication for chronic migraine and chronic rhinitis, with few or no unexpected side effects and a positive socioeconomic impact.

• Ozilia® Migraine

  A CE-marked treatment for the preventive treatment of chronic migraine in adults over 18, based on Kinetic Oscillation Stimulation. It is marketed as a drug-free alternative to migraine medication and is being introduced in Germany, the UK, Italy, Israel and Finland.

• Ozilia® Rhinitis

  A CE-marked treatment for rhinitis, available in the Nordics, selected EU markets, Israel and Saudi Arabia.

1. 1Home - Chordatechordate.com
2. 2Business case - Chordatechordate.com
3. 3General meeting - Chordatechordate.com
4. 4Chordate Medical - Wikidatawikidata.org